



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

NDA 21-073/S-027

Takeda Global Research & Development Center, Inc.  
Attention: Mary Jo Pritza, MPH, PharmD  
Manager, Regulatory Affairs  
475 Half Day Road  
Lincolnshire, IL 60069

Dear Ms. Pritza:

Please refer to your supplemental new drug application dated February 27, 2006, received February 28, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Actos® (pioglitazone HCl), 15 mg, 30 mg, and 45 mg tablets.

We acknowledge receipt of your submission dated May 11, 2006.

Your submission of May 11, 2006, constituted a complete response to our April 6, 2006, action letter.

This supplemental new drug application provides for labeling changes to the **PRECAUTIONS** and **ADVERSE REACTIONS** sections of the package insert.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert) submitted August 28, 2006, (via electronic mail).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-073/S-027.**" Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH  
Food and Drug Administration  
5515 Security Lane  
HFD-001, Suite 5100  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Ms. Jena Weber, Project Manager, at 301-796-1306.

Sincerely,

*{See appended electronic signature page}*

Mary H. Parks, M.D.  
Director  
Division of Metabolism and Endocrinology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure (package insert)

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Mary Parks  
8/30/2006 04:30:35 PM